Author: admin

Heparin Induced Thrombocytopenia Market to Witness Growth by 2032, Estimates DelveInsight | Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma

The Heparin-induced Thrombocytopenia market size was valued approximately USD 125 million in 2022 and is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics.

DelveInsight’s “Heparin-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Heparin-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Heparin-induced Thrombocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

 

To Know in detail about the Heparin-induced Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Heparin-induced Thrombocytopenia Market Forecast

 

Heparin-induced Thrombocytopenia Market Report’s Key Highlights:

  • The Heparin-induced Thrombocytopenia market size was valued approximately USD 125 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • With almost half of the 7MM’s total market size in 2022, the United States had the biggest share of any country in the group.
  • With a market share of almost 77% of all marketed pharmaceuticals, Argatroban had the largest market size in the United States in 2022.
  • Key Heparin-induced Thrombocytopenia Companies: Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma, and others
  • Key Heparin-induced Thrombocytopenia Therapies: argatroban, VLX-1005, bivalirudin, Desirudin (Iprivask™), and others
  • The Heparin-induced Thrombocytopenia epidemiology based on gender analyzed that higher number of cases of Heparin-induced Thrombocytopenia were observed in males as compared to females
  • The Heparin-induced Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Heparin-induced Thrombocytopenia pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics

 

Request a sample for the Heparin-induced Thrombocytopenia Market Report:

https://www.delveinsight.com/report-store/heparin-induced-thrombocytopenia-market

 

Heparin-induced Thrombocytopenia Country based Treatment Analysis: 

The Heparin-induced Thrombocytopenia treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Heparin-induced Thrombocytopenia Therapies that have the potential to transform cancer treatment paradigms and improve patient outcomes.

 

Heparin-induced Thrombocytopenia Epidemiology Insights: 

The report offers historical and forecasted epidemiology insights that helps to understand the target patient population for Heparin-induced Thrombocytopenia. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patients pools. The epidemiology in report is segmented as : 

 

Heparin-induced Thrombocytopenia Epidemiology Segmentation:

  • Total Prevalence of Heparin-induced Thrombocytopenia
  • Prevalent Cases of Heparin-inducedThrombocytopenia by severity
  • Gender-specific Prevalence of Heparin-induced Thrombocytopenia
  • Diagnosed Cases of Episodic and Chronic Heparin-induced Thrombocytopenia

 

“As per DelveInsight, Heparin-Induced Thrombocytopenia Was reported in around 111,000 incident cases in 2022; however, by 2032, the number of cases is predicted to rise in the US.In the United States, there were approximately 63,000 occurrences of thrombosis in heparin-induced thrombocytopenia (HIT) in 2022. This number is predicted to rise at a moderate annual growth rate (CAGR) by 2032.

Japan recorded around 7,700 incident cases of Heparin-Induced Thrombocytopenia (HIT) in 2022. In Japan, these instances are predicted to rise at a moderate CAGR by 2032.”

 

Download the report to understand which factors are driving Heparin-induced Thrombocytopenia epidemiology trends @ Heparin-induced Thrombocytopenia Epidemiology Forecast

 

Emerging Heparin-induced Thrombocytopenia drugs Uptake:

  • VLX-1005, a novel treatment for Heparin-induced Thrombocytopenia (HIT), is presently undergoing Phase II clinical studies. The few main therapies for HIT that are now available are listed below.
  • There are also a number of new oral anticoagulants on the market, such as dabigatran, apixaban, and rivaroxaban, and preliminary data indicates that they could be helpful for HIT, especially in situations where conventional treatments are ineffective. None of these medications have FDA approval for use in HIT, and their efficacy in treating individuals with HIT has not yet been thoroughly evaluated.
  • VLX-1005 was given Fast Track Designation (FTD) by the FDA in June 2022 in order to treat heparin-induced thrombocytopenia

 

Heparin-induced Thrombocytopenia Market Forecast :

  • The research includes a thorough analysis of the past and projected markets for Heparin-induced Thrombocytopenia (HIT), which includes pharmacological outreach in the 7MM nations.
  • Rise in the cases of heparin-induced thrombocytopenia due to various risk factors, such as increased cardiac and orthopedic surgeries and the continued use of unfractionated heparin in hospitalized patients
  • The emergence of direct oral anticoagulants (DOACs) as an alternative for parenteral anticoagulants in acute HIT or HIT with thrombosis is a significant strength in the HIT market. DOACs offer convenience, ease of administration, and comparable efficacy to traditional parenteral anticoagulants 

 

Heparin-induced Thrombocytopenia Therapies and Key Companies

  • argatroban: Mitsubishi Tanabe Pharma
  • VLX-1005: Veralox Therapeutics
  • bivalirudin: The Medicines Company
  • Desirudin (Iprivask™): Canyon Pharma

 

Discover more about therapies set to grab major Heparin-induced Thrombocytopenia market share @ Heparin-induced Thrombocytopenia Treatment Market

 

Scope of the Heparin-induced Thrombocytopenia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Heparin-induced Thrombocytopenia Companies: Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
  • Key Heparin-induced Thrombocytopenia Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
  • Heparin-induced Thrombocytopenia Therapeutic Assessment: Heparin-induced Thrombocytopenia current marketed and Heparin-induced Thrombocytopenia emerging therapies
  • Heparin-induced Thrombocytopenia Market Dynamics: Heparin-induced Thrombocytopenia market drivers and Heparin-induced Thrombocytopenia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Heparin-induced Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Heparin-induced Thrombocytopenia Market Access and Reimbursement 

 

DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Heparin-induced Thrombocytopenia market landscape.

  • Gain Competitive Edge in Indication Market : Understand the current landscape of the heparin-induced thrombocytopenia market, including the competitive environment, key companies developing drugs for Heparin-induced Thrombocytopenia, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
  • Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the heparin-induced thrombocytopenia market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing  with  Heparin-induced Thrombocytopenia. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
  • Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing – reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
  • Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the heparin-induced thrombocytopenia market with clarity and purpose.

 

Discover more about therapies set to grab major Heparin-induced Thrombocytopenia market share @ Heparin-induced Thrombocytopenia market forecast 

 

Table of Contents

1. Heparin-induced Thrombocytopenia Report Introduction

2. Heparin-induced Thrombocytopenia Executive Summary

3. Heparin-induced Thrombocytopenia Overview

4. Heparin-induced Thrombocytopenia- Analytical Perspective In-depth Commercial Assessment

5. Heparin-induced Thrombocytopenia Pipeline Therapeutics

6. Heparin-induced Thrombocytopenia Late Stage Products (Phase II/III)

7. Heparin-induced Thrombocytopenia Mid Stage Products (Phase II)

8. Heparin-induced Thrombocytopenia Early Stage Products (Phase I)

9. Heparin-induced Thrombocytopenia Preclinical Stage Products

10. Heparin-induced Thrombocytopenia Therapeutics Assessment

11. Heparin-induced Thrombocytopenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Heparin-induced Thrombocytopenia Key Companies

14. Heparin-induced Thrombocytopenia Key Products

15. Heparin-induced Thrombocytopenia Unmet Needs

16 . Heparin-induced Thrombocytopenia Market Drivers and Barriers

17. Heparin-induced Thrombocytopenia Future Perspectives and Conclusion

18. Heparin-induced Thrombocytopenia Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Heparin Induced Thrombocytopenia Market to Witness Growth by 2032, Estimates DelveInsight | Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma

People With Meaningful Connections Live Longer: CharmDate Helps

“Build meaningful connections and live longer.”
Recently, a study concludes the meaningful relationships help people live longer.

Discovering a secret to living long lives has been a long-lasting wish of humankind. Different formulas have been discussed and analyzed but a reliable answer hasn’t been found. In recent years, however, new advice and solutions have been presented by researchers. Harvard Study of Adult Development which has been going on for nearly 80 years collected data of major significance to this matter.

Namely, researchers analyzed different aspects of the participants of the study. They considered their failures and successes in personal and professional plans and came up with a surprising discovery: relationships in human lives have a major influence on their quality and longevity.

CharmDate’s experts analyzed this information further and finally presented their conclusion to its users: meaningful connections and relationships make people live longer.

Despite the popular belief that success and material wealth are priorities in one’s life; studies suggest that relationships are the essence of human life instead. Wealthy people with a lack of meaningful connections experience a high level of stress, discomfort, and emotional emptiness. On the other hand, people with stable incomes who do not live luxurious lives but are surrounded by people of trust who fulfill their emotional needs live with less stress and, therefore, can live longer compared to the first group mentioned.

The Influence of Relationships on Longevity

As an international dating platform, CharmDate helps connect singles. This platform allows humans to meet people from different parts of the world and form connections based on personality types, common interests and other areas that make them feel seen, understood and appreciated.

Although its largest user base is singles looking for love interests, this platform can also serve to make friends. Many people build a great connection on CharmDate but they realize they function better as friends than romantic partners. In those cases, they can make long-lasting friendships which enrich their social lives and also affect their emotional state and stability. Relationships of all kinds are considered in the study and finally concludes that meaningful connections make people live longer.

The Role of Romantic Relationships in Human Lives

It is undeniable that romantic relationships have important, if not most important, roles in people’s lives. They influence all other aspects of life. Therefore, it is essential to have a healthy relationship as a foundation for other areas. If a partner is supporting and a relationship is based on trust and support, it affects the confidence, happiness and general well-being of both partners. On the other hand, if a relationship is a source of negative feelings; it is difficult for a person to prosper in other areas as it takes all the positive energy and turns it into negative.

CharmDate experts advise people to be careful when choosing a love interest because their choice will influence all the areas of their lives. If they date a person who empowers their strengths, protects their weaknesses, treats them kindly, and supports them, those traits will project on their professional lives, as well as other relationships. They will be happier in general and it will enhance their other relationships as well.

In order to make matchmaking easier and help people find their soulmates, CharmDate developed an advanced system that connects people based on multiple factors, including their preferences and common interests. Using this platform, singles can find people with whom they can grow strong bonds and enrich their lives. The significance of relationships should not be neglected; instead, people need to embrace them and make wise choices while understanding the importance of those choices.

Numerous filters and innovative features assist CharmDate users in finding people who they can have healthy relationships with. This will not only make their lives happier but also longer!

About CharmDate

CharmDate.com is an international dating site which connects singles from every corner of the world. Its mission is to provide members with a safe, easy-to-use and professional platform, and effective services including EMF Mail, Live Chat, Call, Camshare, Gifts&Flowers, etc.

CharmDate works on multiple end devices. Apart from PC and m-site, members can also download the app from Google Play Store. Dating on the go brings users a fantastic and very different experience!

Media Contact
Company Name: CharmDate
Contact Person: Media Relations
Email: Send Email
Country: HongKong
Website: http://www.charmdate.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: People With Meaningful Connections Live Longer: CharmDate Helps

Glaucoma Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Bayer, SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire

The Glaucoma Market size was valued approximately USD 4,073 million in 2022 and report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the 7MM.

DelveInsight’s “Glaucoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Glaucoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Glaucoma Market Forecast

 

Some of the key facts of the Glaucoma Market Report: 

  • The Glaucoma market size was valued approximately USD 4,073 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • In June 2023, Ciliatech’s implantable device for glaucoma patients is nearing regulatory approval following the disclosure of favorable outcomes from a subsequent two-year post-operative clinical trial.
  • In 2022, the Glaucoma market in the US stood out with the highest market size, reaching USD 2,571 million in net sales revenue among the 7MM. Conversely, the UK exhibited the lowest market size, with approximately USD 132 million.
  • In 2022, it was estimated that there were approximately 7,045,443 diagnosed prevalent cases of Glaucoma in the 7MM. However, the total burden of Glaucoma, including both diagnosed and undiagnosed cases, was estimated to be around 16,632,421 in the same year across the 7MM.
  • The overall Glaucoma market size is projected to increase in the forecast period, driven by the anticipated introduction of emerging therapies such as iDose TR (travoprost intraocular implant), NCX 470, PDP-71, and other treatments.
  • Glaucoma often goes unnoticed in a majority of patients due to various factors. DelveInsight’s estimates indicate that out of the 16,632,421 prevalent Glaucoma cases in the 7MM in 2022, only around 7,045,443 cases are believed to have been formally diagnosed.
  • Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
  • Key Glaucoma Therapies: PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
  • Glaucoma can impact individuals of both genders, but the ratio of male to female Glaucoma patients indicates a higher prevalence among females. In 2022, there were approximately 3,234,796 cases of Glaucoma among males and 3,810,646 cases among females.
  • The Glaucoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Glaucoma pipeline products will significantly revolutionize the Glaucoma market dynamics.

 

Glaucoma Overview

Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment. There are two main types of glaucoma – primary and secondary

 

Get a Free sample for the Glaucoma Market Report:

https://www.delveinsight.com/report-store/glaucoma-market

 

Glaucoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Glaucoma Epidemiology Segmentation:

The Glaucoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Glaucoma
  • Prevalent Cases of Glaucoma by severity
  • Gender-specific Prevalence of Glaucoma
  • Diagnosed Cases of Episodic and Chronic Glaucoma

 

Download the report to understand which factors are driving Glaucoma epidemiology trends @ Glaucoma Epidemiology Forecast

 

Glaucoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Glaucoma market or expected to get launched during the study period. The analysis covers Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Glaucoma Therapies and Key Companies

  • NCX-470: Nicox Ophthalmics
  • TRS01: Tarsier Pharma
  • PDP-716: SPARC
  • PRO-122: Laboratories Sophia
  • EYBELIS/Omidenepag isopropyl/DE-117: Santen Pharmaceutical
  • DE-130A: Santen Pharmaceutical
  • Sepetaprost (DE-126/ONO9054): Santen Pharmaceutical
  • Nyxol: Ocuphire Pharma
  • K-232: Kowa
  • Aflibercept (Eylea, BAY 86-5321): Bayer
  • Travoprost: Alcon Research
  • Timolol: Pfizer
  • timolol/dorzolamide: Merck Sharp & Dohme LLC
  • QPI-1007: Quark Pharmaceuticals

 

Discover more about therapies set to grab major Glaucoma market share @ Glaucoma Treatment Market

 

Glaucoma Market Drivers

  • Rich emerging pipeline
  • Development of advanced antiglaucoma medications
  • Development of treatment methods to tackle the situation of non-adherence
  • Patients-friendly dosage regimes
  • Rise in awareness

 

Glaucoma Market Barriers

  • Approaches to clinical practice
  • Socioeconomic barriers
  • Lack of patient pool due to under diagnosis

 

Scope of the Glaucoma Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Glaucoma Companies: SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire Pharma, Kowa, Bayer, Alcon Research, Pfizer, Merck Sharp & Dohme LLC, Quark Pharmaceuticals, and others
  • Key Glaucoma Therapies: PDP-716, PRO-122, EYBELIS/Omidenepag isopropyl/DE-117, DE-130A, Sepetaprost (DE-126/ONO9054), NCX-470, Nyxol, K-232, Aflibercept (Eylea, BAY 86-5321), Travoprost, timolol/dorzolamide, QPI-1007, and others
  • Glaucoma Therapeutic Assessment: Glaucoma current marketed and Glaucoma emerging therapies
  • Glaucoma Market Dynamics: Glaucoma market drivers and Glaucoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Glaucoma Unmet Needs, KOL’s views, Analyst’s views, Glaucoma Market Access and Reimbursement 

 

To know more about Glaucoma companies working in the treatment market, visit @ Glaucoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Glaucoma Market Report Introduction

2. Executive Summary for Glaucoma

3. SWOT analysis of Glaucoma

4. Glaucoma Patient Share (%) Overview at a Glance

5. Glaucoma Market Overview at a Glance

6. Glaucoma Disease Background and Overview

7. Glaucoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Glaucoma 

9. Glaucoma Current Treatment and Medical Practices

10. Glaucoma Unmet Needs

11. Glaucoma Emerging Therapies

12. Glaucoma Market Outlook

13. Country-Wise Glaucoma Market Analysis (2020–2034)

14. Glaucoma Market Access and Reimbursement of Therapies

15. Glaucoma Market Drivers

16. Glaucoma Market Barriers

17.  Glaucoma Appendix

18. Glaucoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glaucoma Market to Observe Impressive Growth During the Forecast Period (2024-2034), Evaluates DelveInsight | Bayer, SPARC, Laboratories Sophia, Santen Pharmaceutical, Nicox Ophthalmics, Ocuphire

Gastroesophageal Reflux Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Phantom Pharmaceuticals, Sinorda Biomed

The Gastroesophageal Reflux Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

DelveInsight’s “Gastroesophageal Reflux Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Gastroesophageal Reflux Disease, historical and forecasted epidemiology as well as the Gastroesophageal Reflux Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Gastroesophageal Reflux Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroesophageal Reflux Disease Market Forecast

 

Some of the key facts of the Gastroesophageal Reflux Disease Market Report: 

  • The Gastroesophageal Reflux Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In March 2024, Implantica commenced the premarket approval process with the US Food and Drug Administration (FDA) for its RefluxStop treatment intended for gastroesophageal reflux disease (GERD). The Liechtenstein-based company aims to obtain approval for RefluxStop through the US FDA’s premarket approval application (PMA) modular review program. This approach permits companies to complete sections, known as modules, at various intervals. Final confirmation is granted once all sections of the PMA are completed. Additionally, the program facilitates ongoing review and feedback from the FDA as modules are submitted.
  • In May 2023, Phathom Pharmaceuticals refiled its New Drug Application with the FDA for vonoprazan, aiming to secure approval for treating erosive gastroesophageal reflux disease (GERD), also known as erosive esophagitis.
  • According to Marco G. Patti (2020), a significant portion of Americans, estimated at 25% to 40%, encounter symptomatic gastroesophageal reflux disease (GERD) at various times, with approximately 7% to 10% experiencing daily symptoms. While many manage their symptoms using over-the-counter (OTC) medications and without seeking medical advice, the actual GERD prevalence is likely higher.
  • Key Gastroesophageal Reflux Disease Companies: Phantom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
  • Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
  • The Gastroesophageal Reflux Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroesophageal Reflux Disease pipeline products will significantly revolutionize the Gastroesophageal Reflux Disease market dynamics.

 

Gastroesophageal Reflux Disease Overview

Gastroesophageal Reflux Disease (GERD) is a chronic digestive disorder characterized by the reflux of stomach acid into the esophagus, causing irritation and inflammation. It occurs when the lower esophageal sphincter (LES), a ring of muscle between the esophagus and stomach, becomes weak or relaxes inappropriately, allowing stomach contents to flow back up into the esophagus.

 

Get a Free sample for the Gastroesophageal Reflux Disease Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

 

Gastroesophageal Reflux Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Gastroesophageal Reflux Disease Epidemiology Segmentation:

The Gastroesophageal Reflux Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Gastroesophageal Reflux Disease
  • Prevalent Cases of Gastroesophageal Reflux Disease by severity
  • Gender-specific Prevalence of Gastroesophageal Reflux Disease
  • Diagnosed Cases of Episodic and Chronic Gastroesophageal Reflux Disease

 

Download the report to understand which factors are driving Gastroesophageal Reflux Disease epidemiology trends @ Gastroesophageal Reflux Disease Epidemiology Forecast

 

Gastroesophageal Reflux Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroesophageal Reflux Disease market or expected to get launched during the study period. The analysis covers Gastroesophageal Reflux Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroesophageal Reflux Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Gastroesophageal Reflux Disease Therapies and Key Companies

  • Vonoprazan: Phathom Pharmaceuticals
  • X842: Sinorda Biomedicine
  • BLI5100: Sebela Pharmaceutical
  • Linaprazan glurate: Cinclus Pharma
  • Naronapride: Renexxion Ireland
  • Fexuprazan: Daewoong Pharmaceutical
  • IN-C003: HK inno.N
  • IN-C002: HK inno.N
  • CKD-382: Chong Kun Dang Pharmaceutical
  • IN-C004: HK inno.N
  • AD-214: Addpharma
  • JP-1366: Jeil Pharmaceuticals
  • Naronapride: Renexxion
  • Fexuprazan: Daewoong Pharmaceutical

 

Discover more about therapies set to grab major Gastroesophageal Reflux Disease market share @ Gastroesophageal Reflux Disease Treatment Landscape

 

Gastroesophageal Reflux Disease Market Strengths

  • Lifestyle changes, including dietary adjustments, weight management, and elevating the head of the bed, offer non-pharmacological approaches to managing GERD and reducing symptom severity.
  • There is a growing awareness of GERD among both healthcare professionals and the general population. This increased awareness leads to earlier diagnosis and improved management.

 

Gastroesophageal Reflux Disease Market Opportunities

  • Multidisciplinary teams involving gastroenterologists, dietitians, psychologists, and surgeons can work collaboratively to provide comprehensive care and support for GERD patients.
  • Promising new drugs, such as naronapride, vonoprazan, and BLI5100 are being developed to address GERD and its complications, providing potential alternatives for patients who are unresponsive to current treatments.

 

Scope of the Gastroesophageal Reflux Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Gastroesophageal Reflux Disease Companies: Phathom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others
  • Key Gastroesophageal Reflux Disease Therapies: Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others
  • Gastroesophageal Reflux Disease Therapeutic Assessment: Gastroesophageal Reflux Disease current marketed and Gastroesophageal Reflux Disease emerging therapies
  • Gastroesophageal Reflux Disease Market Dynamics: Gastroesophageal Reflux Disease market drivers and Gastroesophageal Reflux Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Gastroesophageal Reflux Disease Unmet Needs, KOL’s views, Analyst’s views, Gastroesophageal Reflux Disease Market Access and Reimbursement 

 

To know more about Gastroesophageal Reflux Disease companies working in the treatment market, visit @ Gastroesophageal Reflux Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Gastroesophageal Reflux Disease Market Report Introduction

2. Executive Summary for Gastroesophageal Reflux Disease

3. SWOT analysis of Gastroesophageal Reflux Disease

4. Gastroesophageal Reflux Disease Patient Share (%) Overview at a Glance

5. Gastroesophageal Reflux Disease Market Overview at a Glance

6. Gastroesophageal Reflux Disease Disease Background and Overview

7. Gastroesophageal Reflux Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroesophageal Reflux Disease 

9. Gastroesophageal Reflux Disease Current Treatment and Medical Practices

10. Gastroesophageal Reflux Disease Unmet Needs

11. Gastroesophageal Reflux Disease Emerging Therapies

12. Gastroesophageal Reflux Disease Market Outlook

13. Country-Wise Gastroesophageal Reflux Disease Market Analysis (2019–2032)

14. Gastroesophageal Reflux Disease Market Access and Reimbursement of Therapies

15. Gastroesophageal Reflux Disease Market Drivers

16. Gastroesophageal Reflux Disease Market Barriers

17.  Gastroesophageal Reflux Disease Appendix

18. Gastroesophageal Reflux Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastroesophageal Reflux Disease Market and Epidemiology 2032: Treatment Market, Therapies, Companies, FDA Approvals, Epidemiology and Forecast by DelveInsight | Phantom Pharmaceuticals, Sinorda Biomed

Inflammatory Bowel Disease Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport

The Inflammatory Bowel Disease Market Forecast and Insights report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the 7MM.

DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Inflammatory Bowel Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Inflammatory Bowel Disease Market Forecast

 

Some of the key facts of the Inflammatory Bowel Disease Market Report: 

  • The Inflammatory Bowel Disease market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In December 2023, Insilico Medicine, a clinical-stage biotechnology company employing generative artificial intelligence (AI), has launched the inaugural human trial for ISM5411. This compound, a poly hydroxylase domain (PHD) 1/2 inhibitor, holds promise as a pioneering treatment for inflammatory bowel disease (IBD).
  • During the year 2021, there were 3,835,000 prevalent cases of IBD in the 7MM. In all of the regions, this count is predicted to rise during the projection period
  • There were 634,000 and 1,021,000 prevalent cases of CD and UC, respectively, in the EU-5 region in 2021
  • It was discovered that the overall diagnosed prevalence of IBD in the 7MM increased steadily during the course of the study. In the 7MM, 2,743,000 cases of IBD were identified in 2021. In 2021, there were the most diagnosed cases of IBD in the United States. In the US, there were over 1,323,000 diagnosed cases of IBD in 2021
  • The introduction of numerous important medications during the past ten years has changed how inflammatory bowel disease is managed. Adalimumab, infliximab, and vedolizumab medications like HUMIRA (adalimumab, AbbVie), REMICADE (Janssen), and ENTYVIO (Takeda) have all assisted patients in achieving significant endpoints including clinical remission and mucosal healing.
  • Key Inflammatory Bowel Disease Companies: Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
  • Key Inflammatory Bowel Disease Therapies: Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others
  • The Inflammatory Bowel Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Inflammatory Bowel Disease pipeline products will significantly revolutionize the Inflammatory Bowel Disease market dynamics.

 

Inflammatory Bowel Disease Overview

Chronic and complicated, inflammatory bowel disease (IBD) is brought on by immune system dysregulation brought on by genetic, epigenetic, microbial, and environmental variables.

 

Get a Free sample for the Inflammatory Bowel Disease Market Report:

https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market

 

Inflammatory Bowel Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Inflammatory Bowel Disease Epidemiology Segmentation:

The Inflammatory Bowel Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Inflammatory Bowel Disease
  • Prevalent Cases of Inflammatory Bowel Disease by severity
  • Gender-specific Prevalence of Inflammatory Bowel Disease
  • Diagnosed Cases of Episodic and Chronic Inflammatory Bowel Disease

 

Download the report to understand which factors are driving Inflammatory Bowel Disease epidemiology trends @ Inflammatory Bowel Disease Epidemiology Forecast

 

Inflammatory Bowel Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inflammatory Bowel Disease market or expected to get launched during the study period. The analysis covers Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inflammatory Bowel Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Inflammatory Bowel Disease Therapies and Key Companies

  • Mirikizumab: Eli Lilly and Company
  • Filgotinib: Gilead/ Galapagos
  • AMT-101: Applied Molecular Transport
  • PN-943: Protagonist Therapeutics
  • Tremfya: Janssen
  • Brazikumab: AstraZeneca

 

Discover more about therapies set to grab major Inflammatory Bowel Disease market share @ Inflammatory Bowel Disease Treatment Market

 

Scope of the Inflammatory Bowel Disease Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Inflammatory Bowel Disease Companies: Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport, Protagonist Therapeutics, Janssen, AstraZeneca, Pharmacosmos A/S, 4SC AG, Pharmacosmos A/S, Vifor Pharma, Astellas Pharma, Shield Therapeutics, Takeda, Ocera Therapeutics, Sanofi, Morphic Therapeutic, Inc., Bausch Health Americas, Inc., Qu Biologics Inc., Vifor Pharma, and others
  • Key Inflammatory Bowel Disease Therapies: Mirikizumab, Filgotinib, AMT-101, PN-943, Tremfya, Brazikumab, Iron Isomaltoside 1000, SC12267 (4SC-101), Monofer, Ferinject, fidaxomicin, Ferric Maltol, Lubiprostone, AST-120, Ustekinumab, Nolpitantium besylate, MORF-057, Balsalazide Disodium, QBECO, Ferric carboxymaltose, and others
  • Inflammatory Bowel Disease Therapeutic Assessment: Inflammatory Bowel Disease current marketed and Inflammatory Bowel Disease emerging therapies
  • Inflammatory Bowel Disease Market Dynamics: Inflammatory Bowel Disease market drivers and Inflammatory Bowel Disease market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Inflammatory Bowel Disease Unmet Needs, KOL’s views, Analyst’s views, Inflammatory Bowel Disease Market Access and Reimbursement 

 

To know more about Inflammatory Bowel Disease companies working in the treatment market, visit @ Inflammatory Bowel Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Inflammatory Bowel Disease Market Report Introduction

2. Executive Summary for Inflammatory Bowel Disease

3. SWOT analysis of Inflammatory Bowel Disease

4. Inflammatory Bowel Disease Patient Share (%) Overview at a Glance

5. Inflammatory Bowel Disease Market Overview at a Glance

6. Inflammatory Bowel Disease Disease Background and Overview

7. Inflammatory Bowel Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Inflammatory Bowel Disease 

9. Inflammatory Bowel Disease Current Treatment and Medical Practices

10. Inflammatory Bowel Disease Unmet Needs

11. Inflammatory Bowel Disease Emerging Therapies

12. Inflammatory Bowel Disease Market Outlook

13. Country-Wise Inflammatory Bowel Disease Market Analysis (2019–2032)

14. Inflammatory Bowel Disease Market Access and Reimbursement of Therapies

15. Inflammatory Bowel Disease Market Drivers

16. Inflammatory Bowel Disease Market Barriers

17.  Inflammatory Bowel Disease Appendix

18. Inflammatory Bowel Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Inflammatory Bowel Disease Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Eli Lilly and Company, Gilead, Galapagos, Applied Molecular Transport

Ischemia Reperfusion Injury Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Dompé Farmaceutici, Stealth BioTherapeutics, ICON Clinical

The Ischemia Reperfusion Injury market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Ischemia Reperfusion Injury market dynamics.

DelveInsight’s “Ischemia Reperfusion Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ischemia Reperfusion Injury, historical and forecasted epidemiology as well as the Ischemia Reperfusion Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Ischemia Reperfusion Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ischemia Reperfusion Injury Market Forecast

 

Some of the key facts of the Ischemia Reperfusion Injury Market Report

  • The Ischemia Reperfusion Injury market size is anticipated to grow with a significant CAGR during the study period (2019-2032)  
  • The tissue damage that happens once the blood flow returns to the tissue following a period of oxygen deprivation is known as ischemia-reperfusion injury (IRI). IHD, which affects 128 million people worldwide, is the primary cause of morbidity. 
  • In the United States alone, ischemic injury incidence from myocardial infarction, stroke, and other thrombotic events affects more than 1.3 million people annually.  
  • Ischemic heart disease, which leads to acute myocardial infarction and heart failure, is responsible for over 9 million preventable deaths each year.  
  • Key Ischemia Reperfusion Injury Companies: Pfizer, GNT Pharma, United Therapeutics, GlaxoSmithKline, ICON Clinical Research, Dompé Farmaceutici, Medicure, and others 
  • Key Ischemia-Reperfusion Injury Therapies: atorvastatin, Neu2000KWL group, Treprostinil, rosiglitazone, Bendavia (MTP-131), Reparixin, (MC-1) Pyridoxal 5′-phosphate, and others 
  • The Ischemia Reperfusion Injury epidemiology based on gender analyzed that Males have a higher prevalence of Ischemia Reperfusion Injury than females. Most primary causes of IRI, including stroke, thrombosis, and others, affect males more than females due to various factors

 

Ischemia Reperfusion Injury Overview

When blood flow, perfusion, and concurrent reoxygenation are restored to an organ or area after an initial inadequate blood supply after a crucial time period, ischemia reperfusion (IR) injury happens. In many pathological circumstances in emergency care, such as trauma, Ischemia Reperfusion Injury, myocardial infarction, and post-cardiac arrest syndrome, it leads to mortality and morbidity. 

 

Request a sample for the Ischemia Reperfusion Injury Market Report:

https://www.delveinsight.com/report-store/ischemia-reperfusion-injury-market

 

Ischemia Reperfusion Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ischemia Reperfusion Injury Epidemiology Segmentation:

The Ischemia Reperfusion Injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Ischemia Reperfusion Injury
  • Prevalent Cases of Ischemia Reperfusion Injury by severity
  • Gender-specific Prevalence of Ischemia Reperfusion Injury
  • Diagnosed Cases of Episodic and Chronic Ischemia Reperfusion Injury 

 

Download the report to understand which factors are driving Ischemia Reperfusion Injury epidemiology trends @ Ischemia Reperfusion Injury Epidemiological Insights 

 

Ischemia Reperfusion Injury Market  

The dynamics of the Ischemia Reperfusion Injury market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as TRO40303, Atorvastatin, and others during the forecasted period 2019-2032. 

 

Ischemia Reperfusion Injury Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ischemia Reperfusion Injury market or expected to get launched during the study period. The analysis covers Ischemia Reperfusion Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ischemia Reperfusion Injury Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Ischemia Reperfusion Injury Therapies and Key Companies

  • atorvastatin: Pfizer
  • Neu2000KWL group: GNT Pharma
  • Treprostinil: United Therapeutics
  • rosiglitazone: GlaxoSmithKline
  • Bendavia (MTP-131): ICON Clinical Research
  • Reparixin: Dompé Farmaceutici
  • (MC-1) Pyridoxal 5′-phosphate: Medicure

 

To know more about Ischemia Reperfusion Injury treatment, visit @ Ischemia Reperfusion Injury Medications 

 

Scope of the Ischemia Reperfusion Injury Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Ischemia Reperfusion Injury Companies: Pfizer, GNT Pharma, United Therapeutics, GlaxoSmithKline, ICON Clinical Research, Dompé Farmaceutici, Medicure, and others
  • Key Ischemia Reperfusion Injury Therapies: atorvastatin, Neu2000KWL group, Treprostinil, rosiglitazone, Bendavia (MTP-131), Reparixin, (MC-1) Pyridoxal 5′-phosphate, and others
  • Therapeutic Assessment: Ischemia Reperfusion Injury current marketed and Ischemia Reperfusion Injury emerging therapies
  • Ischemia Reperfusion Injury Market Dynamics: Ischemia Reperfusion Injury market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Ischemia Reperfusion Injury Unmet Needs, KOL’s views, Analyst’s views, Ischemia Reperfusion Injury  Market Access and Reimbursement 

 

Discover more about therapies set to grab major Ischemia Reperfusion Injury market share @ Ischemia Reperfusion Injury market forecast 

 

Table of Contents 

1. Ischemia Reperfusion Injury Market Report Introduction

2. Executive Summary for Ischemia Reperfusion Injury

3. SWOT analysis of Ischemia Reperfusion Injury

4. Ischemia Reperfusion Injury Patient Share (%) Overview at a Glance

5. Ischemia Reperfusion Injury Market Overview at a Glance

6. Ischemia Reperfusion Injury Disease Background and Overview

7. Ischemia Reperfusion Injury Epidemiology and Patient Population

8. Country-Specific Patient Population of Ischemia Reperfusion Injury 

9. Ischemia Reperfusion Injury Current Treatment and Medical Practices

10. Ischemia Reperfusion Injury Unmet Needs

11. Ischemia Reperfusion Injury Emerging Therapies

12. Ischemia Reperfusion Injury Market Outlook

13. Country-Wise Ischemia Reperfusion Injury Market Analysis (2019–2032)

14. Ischemia Reperfusion Injury Market Access and Reimbursement of Therapies

15. Ischemia Reperfusion Injury Market drivers

16. Ischemia Reperfusion Injury Market barriers

17.  Ischemia Reperfusion Injury Appendix

18. Ischemia Reperfusion Injury Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemia Reperfusion Injury Market is Predicted to Exhibit Remarkable Growth During the Forecast Period (2023-2032), Analyzes DelveInsight | Dompé Farmaceutici, Stealth BioTherapeutics, ICON Clinical

Ischemic Stroke Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie

The Ischemic Stroke market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ischemic Stroke pipeline products will significantly revolutionize the Ischemic Stroke market dynamics.

DelveInsight’s “Ischemic Stroke Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Ischemic Stroke, historical and forecasted epidemiology as well as the Ischemic Stroke market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Ischemic Stroke market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ischemic Stroke Market Forecast

 

Some of the key facts of the Ischemic Stroke Market Report: 

  • The Ischemic Stroke market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
  • In January 2024, Aruna Bio has revealed intentions to commence a Phase I/II clinical study for AB126, aimed at addressing acute ischemic stroke, during the initial six months of 2024. This determination follows the clearance by the US Food and Drug Administration (FDA) of the company’s investigational new drug (IND) application pertaining to its primary program, AB126.
  • As per the study conducted by Edward C Jauch et. al., nearly 800,000 people suffer from strokes each year in the United States and 82–92% of these strokes are ischemic. Stroke is the fifth leading cause of adult death and disability 
  • According to the World Health Organization (WHO), an estimated 15 million individuals worldwide suffer from stroke each year. Of these, 5 million die, and another 5 million are left permanently disabled. 
  • As per Stroke Association of the United Kingdom, Up to 25% of childhood Ischemic strokes are linked to congenital heart disease 
  • Key Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others 
  • Key Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others 
  • The Ischemic Stroke epidemiology based on gender analyzed that men are at higher risk for Ischemic Stroke than women

 

Ischemic Stroke Overview

Ischemic Stroke (AIS) occurs when blood flow through a brain artery is blocked by a clot- amass of thickened blood. Clots are either thrombotic or embolic, depending on where they develop within the body. A thrombotic stroke, more common of the two, occurs when a clot forms within an artery in the brain. An embolic stroke occurs when a clot or small piece of plaque (fatty deposit) breaks off from elsewhere in the body, such as the heart, and travels through the bloodstream only to become stuck in a narrower vessel in the brain.

 

Get a Free sample for the Ischemic Stroke Market Report:

https://www.delveinsight.com/report-store/ischemic-stroke-market

 

Ischemic Stroke Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Ischemic Stroke Epidemiology Segmentation:

The Ischemic Stroke market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Ischemic Stroke
  • Prevalent Cases of Ischemic Stroke by severity
  • Gender-specific Prevalence of Ischemic Stroke
  • Diagnosed Cases of Episodic and Chronic Ischemic Stroke

 

Download the report to understand which factors are driving Ischemic Stroke epidemiology trends @ Ischemic Stroke Epidemiological Insights

 

Ischemic Stroke Market  

The dynamics of the Ischemic Stroke market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032.

 

Ischemic Stroke Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ischemic Stroke market or expected to get launched during the study period. The analysis covers Ischemic Stroke market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Ischemic Stroke Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Ischemic Stroke Therapies and Key Companies

  • BMS986177: Bristol-Myers Squibb
  • LT-3001: Lumosa Therapeutics
  • Elezanumab: Abbvie
  • MultiStem: Athersys/Healios K.K.

 

To know more about Ischemic Stroke treatment, visit @ Ischemic Stroke Medications

 

Scope of the Ischemic Stroke Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Ischemic Stroke Companies: Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie, and others
  • Key Ischemic Stroke Therapies: MultiStem, BMS986177, LT-3001, Elezanumab, and others
  • Ischemic Stroke Therapeutic Assessment: Ischemic Stroke current marketed and Ischemic Stroke emerging therapies
  • Ischemic Stroke Market Dynamics: Ischemic Stroke market drivers and barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Ischemic Stroke Unmet Needs, KOL’s views, Analyst’s views, Ischemic Stroke  Market Access and Reimbursement

 

Discover more about therapies set to grab major Ischemic Stroke market share @ Ischemic Stroke market forecast

 

Table of Contents 

1. Ischemic Stroke Market Report Introduction

2. Executive Summary for Ischemic Stroke

3. SWOT analysis of Ischemic Stroke

4. Ischemic Stroke Patient Share (%) Overview at a Glance

5. Ischemic Stroke Market Overview at a Glance

6. Ischemic Stroke Disease Background and Overview

7. Ischemic Stroke Epidemiology and Patient Population

8. Country-Specific Patient Population of Ischemic Stroke 

9. Ischemic Stroke Current Treatment and Medical Practices

10. Ischemic Stroke Unmet Needs

11. Ischemic Stroke Emerging Therapies

12. Ischemic Stroke Market Outlook

13. Country-Wise Ischemic Stroke Market Analysis (2019–2032)

14. Ischemic Stroke Market Access and Reimbursement of Therapies

15. Ischemic Stroke Market drivers

16. Ischemic Stroke Market barriers

17.  Ischemic Stroke Appendix

18. Ischemic Stroke Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Ischemic Stroke Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Athersys/Healios K.K., Bristol-Myers Squibb, Lumosa Therapeutics, Abbvie

Kidney Transplant Rejection Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharma

The Kidney Transplant Rejection Market Forecast and Insights report offers an in-depth understanding of the Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Kidney Transplant Rejection market trends in the 7MM.

DelveInsight’s “Kidney Transplant Rejection Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Kidney Transplant Rejection, historical and forecasted epidemiology as well as the Kidney Transplant Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Kidney Transplant Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Kidney Transplant Rejection Market Forecast

 

Some of the key facts of the Kidney Transplant Rejection Market Report: 

  • The Kidney Transplant Rejection market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In September 2023, Eledon Pharmaceuticals initiated dosing for the initial participant in the Phase II BESTOW trial, focusing on tegoprubart’s role in preventing organ rejection following kidney transplantation. This multicenter study, employing an active comparator with two arms, aims to evaluate the pharmacokinetics, efficacy, and safety of tegoprubart, an anti-CD40 ligand antibody, compared to the calcineurin inhibitor tacrolimus.
  • In a research involving 22,730 kidney recipients in the UK, 23.7% (5,389) of the transplanted kidneys experienced graft failure over a median follow-up period of 5 years. The primary reasons for graft failure were death with a functioning graft (40.8%) and alloimmune pathology (25.0%) as reported by Burton et al. in 2018.
  • Key Kidney Transplant Rejection Companies: Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others
  • Key Kidney Transplant Rejection Therapies: MDR-101, MDR-102, FCR001, Clazakizumab, Tegoprubart, Sonazoid, Belatacept, AT-1501, Simulect, belimumab, CFZ533 – MMF – CS, Imlifidase, tacrolimus, BIVV020 (SAR445088), Cyclosporine, and others
  • The Kidney Transplant Rejection epidemiology based on gender analyzed that there is no gender-based difference; however, older individuals have a higher incidence of kidney transplant rejection than young individuals.
  • The Kidney Transplant Rejection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Kidney Transplant Rejection pipeline products will significantly revolutionize the Kidney Transplant Rejection market dynamics.

 

Kidney Transplant Rejection Overview

Kidney transplant rejection refers to the body’s immune system recognizing and attacking the transplanted kidney as if it were a foreign object. This immune response can occur because the body perceives the transplanted kidney’s cells (graft) as different from its own, leading to an attempt to eliminate or “reject” the new organ.

 

Get a Free sample for the Kidney Transplant Rejection Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/kidney-transplant-rejection-market

 

Kidney Transplant Rejection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Kidney Transplant Rejection Epidemiology Segmentation:

The Kidney Transplant Rejection market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Kidney Transplant Rejection
  • Prevalent Cases of Kidney Transplant Rejection by severity
  • Gender-specific Prevalence of Kidney Transplant Rejection
  • Diagnosed Cases of Episodic and Chronic Kidney Transplant Rejection

 

Download the report to understand which factors are driving Kidney Transplant Rejection epidemiology trends @ Kidney Transplant Rejection Epidemiology Forecast

 

Kidney Transplant Rejection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Kidney Transplant Rejection market or expected to get launched during the study period. The analysis covers Kidney Transplant Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Kidney Transplant Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Kidney Transplant Rejection Therapies and Key Companies

  • MDR-101: Medeor Therapeutics
  • MDR-102: Medeor Therapeutics
  • FCR001: Talaris Therapeutics
  • Clazakizumab: CSL Behring
  • Tegoprubart: Eledon Pharmaceuticals
  • Sonazoid: GE Healthcare
  • Belatacept: Viela Bio
  • AT-1501: Eledon Pharmaceuticals
  • Simulect: Neovii Biotech
  • belimumab: GlaxoSmithKline
  • CFZ533 – MMF – CS: Novartis
  • Imlifidase: Hansa Biopharma AB
  • tacrolimus: Astellas Pharma Inc
  • BIVV020 (SAR445088): Sanofi
  • Cyclosporine: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Kidney Transplant Rejection market share @ Kidney Transplant Rejection Treatment Landscape

 

Scope of the Kidney Transplant Rejection Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Kidney Transplant Rejection Companies: Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharmaceuticals, GE Healthcare, Viela Bio, Eledon Pharmaceuticals, Neovii Biotech, GlaxoSmithKline, Novartis, Hansa Biopharma AB, Astellas Pharma Inc, Sanofi, Bristol-Myers Squibb, and others
  • Key Kidney Transplant Rejection Therapies: MDR-101, MDR-102, FCR001, Clazakizumab, Tegoprubart, Sonazoid, Belatacept, AT-1501, Simulect, belimumab, CFZ533 – MMF – CS, Imlifidase, tacrolimus, BIVV020 (SAR445088), Cyclosporine, and others
  • Kidney Transplant Rejection Therapeutic Assessment: Kidney Transplant Rejection current marketed and Kidney Transplant Rejection emerging therapies
  • Kidney Transplant Rejection Market Dynamics: Kidney Transplant Rejection market drivers and Kidney Transplant Rejection market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Kidney Transplant Rejection Unmet Needs, KOL’s views, Analyst’s views, Kidney Transplant Rejection Market Access and Reimbursement 

 

To know more about Kidney Transplant Rejection companies working in the treatment market, visit @ Kidney Transplant Rejection Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Kidney Transplant Rejection Market Report Introduction

2. Executive Summary for Kidney Transplant Rejection

3. SWOT analysis of Kidney Transplant Rejection

4. Kidney Transplant Rejection Patient Share (%) Overview at a Glance

5. Kidney Transplant Rejection Market Overview at a Glance

6. Kidney Transplant Rejection Disease Background and Overview

7. Kidney Transplant Rejection Epidemiology and Patient Population

8. Country-Specific Patient Population of Kidney Transplant Rejection 

9. Kidney Transplant Rejection Current Treatment and Medical Practices

10. Kidney Transplant Rejection Unmet Needs

11. Kidney Transplant Rejection Emerging Therapies

12. Kidney Transplant Rejection Market Outlook

13. Country-Wise Kidney Transplant Rejection Market Analysis (2019–2032)

14. Kidney Transplant Rejection Market Access and Reimbursement of Therapies

15. Kidney Transplant Rejection Market Drivers

16. Kidney Transplant Rejection Market Barriers

17.  Kidney Transplant Rejection Appendix

18. Kidney Transplant Rejection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Kidney Transplant Rejection Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Medeor Therapeutics, Talaris Therapeutics, CSL Behring, Eledon Pharma

Lewy Body Dementia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition

The Lewy Body Dementia Market Forecast and Insights report offers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the 7MM.

DelveInsight’s “Lewy Body Dementia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Lewy Body Dementia, historical and forecasted epidemiology as well as the Lewy Body Dementia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Lewy Body Dementia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Lewy Body Dementia Market Forecast

 

Some of the key facts of the Lewy Body Dementia Market Report: 

  • The Lewy Body Dementia market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In August 2023, EIP Pharma, headquartered in the United States, has administered the initial dose to the first patient in its RewinD-LB clinical trial, investigating neflamapimod for the management of individuals with dementia with Lewy bodies (DLB). Building upon positive results from a Phase IIa trial, AscenD-LB, the biopharmaceutical company has initiated its Phase IIb trial (NCT05869669) of neflamapimod (also known as VX-745).
  • The condition typically lasts between 5 and 7 years from the time of diagnosis until death, but it can last anywhere between 2 and 20 years
  • Age is thought to be the biggest risk factor. The majority of those who get the condition are above 50. There is no known lifestyle factor that increases a person’s risk for Lewy Body Dementia
  • In order to free dementia with Lewy bodies (DLB) from the influence of approved treatments, Cognition Therapeutics has been working hard. 120 adults with DLB, aged 50 to 80, are participating in a phase 2, double-blind, placebo-controlled research (NCT0522514) that is evaluating the company’s investigational drug, CT1812. The project, which is funded by a $30 million grant from the National Institute on Ageing of the National Institutes of Health, will evaluate safety results as well as adjustments in cognitive function, physical activity, and pharmacokinetic and pharmacodynamic biomarkers
  • Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others
  • Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others
  • The Lewy Body Dementia epidemiology based on gender analyzed that through various secondary studies it can be found that LBD more commonly affects males than females
  • The Lewy Body Dementia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Lewy Body Dementia pipeline products will significantly revolutionize the Lewy Body Dementia market dynamics.

 

Lewy Body Dementia Overview

The National Institute of Health (NIH) describes Lewy body dementia (LBD) as a condition characterised by aberrant accumulations of the protein alpha-synuclein in the brain. These deposits, also known as Lewy bodies, modify certain brain chemicals, and these modifications can result in issues with thought, movement, behaviour, and mood. One of the most prevalent types of dementia is Lewy body dementia.

 

Get a Free sample for the Lewy Body Dementia Market Report 

https://www.delveinsight.com/report-store/lewy-body-dementia-market

 

Lewy Body Dementia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Lewy Body Dementia Epidemiology Segmentation:

The Lewy Body Dementia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Lewy Body Dementia
  • Prevalent Cases of Lewy Body Dementia by severity
  • Gender-specific Prevalence of Lewy Body Dementia
  • Diagnosed Cases of Episodic and Chronic Lewy Body Dementia

 

Download the report to understand which factors are driving Lewy Body Dementia epidemiology trends @ Lewy Body Dementia Epidemiology Forecast

 

Lewy Body Dementia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lewy Body Dementia market or expected to get launched during the study period. The analysis covers Lewy Body Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Lewy Body Dementia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Lewy Body Dementia Therapies and Key Companies

  • E2027: Eisai
  • Neflamapimod: EIP Pharma
  • K0706: Sun Pharma
  • RVT-101: Axovant Sciences Ltd.
  • CT1812: Cognition Therapeutics
  • K0706: Cephalon
  • Irsenontrine: Eisai Inc.
  • Neflamapimod: EIP Pharma Inc
  • Donepezil: Eisai Co., Ltd.
  • ATH-1017: Athira Pharma
  • Galantamine: Ortho-McNeil Neurologics, Inc.
  • Memantine: H. Lundbeck A/S
  • Nelotanserin: Axovant Sciences Ltd.
  • DatSCAN: GE Healthcare
  • NYX-458: Aptinyx
  • N-831(Traneurocin): NeuroActiva, Inc.
  • CST-103, CST-107: CuraSen Therapeutics, Inc.
  • Pimavanserin: ACADIA Pharmaceuticals Inc.

 

Discover more about therapies set to grab major Lewy Body Dementia market share @ Lewy Body Dementia Treatment Market

 

Lewy Body Dementia Market Strengths

  • Increasing research and development to understand the diversity of the disease might improve the diagnosis of LBD thereby resulting in a lucrative market opportunity.
  • Current treatments are effective in relieving the symptoms and improving the quality of life of the patients.

 

Lewy Body Dementia Market Opportunities

  • Several organizations are actively working to provide information and increase awareness of such disorders.
  • There is only one approved treatment option for LBD which opens a platform of new therapies to boost the market ofLBD.
  • The pipeline for PMM is narrow as there is limited R&D activity

 

Scope of the Lewy Body Dementia Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Lewy Body Dementia Companies: Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics, Cephalon, Athira Pharma, Ortho-McNeil Neurologics, Inc., H. Lundbeck A/S, Axovant Sciences Ltd., GE Healthcare, Aptinyx, NeuroActiva, Inc., CuraSen Therapeutics, Inc., ACADIA Pharmaceuticals Inc., and others
  • Key Lewy Body Dementia Therapies: E2027, Neflamapimod, K0706, RVT-101, CT1812, K0706, Irsenontrine, Donepezil, ATH-1017, Galantamine, Memantine, Nelotanserin, DatSCAN, NYX-458, N-831(Traneurocin), CST-103, CST-107, Pimavanserin, and others
  • Lewy Body Dementia Therapeutic Assessment: Lewy Body Dementia current marketed and Lewy Body Dementia emerging therapies
  • Lewy Body Dementia Market Dynamics: Lewy Body Dementia market drivers and Lewy Body Dementia market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Lewy Body Dementia Unmet Needs, KOL’s views, Analyst’s views, Lewy Body Dementia Market Access and Reimbursement 

 

To know more about Lewy Body Dementia companies working in the treatment market, visit @ Lewy Body Dementia Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Lewy Body Dementia Market Report Introduction

2. Executive Summary for Lewy Body Dementia

3. SWOT analysis of Lewy Body Dementia

4. Lewy Body Dementia Patient Share (%) Overview at a Glance

5. Lewy Body Dementia Market Overview at a Glance

6. Lewy Body Dementia Disease Background and Overview

7. Lewy Body Dementia Epidemiology and Patient Population

8. Country-Specific Patient Population of Lewy Body Dementia 

9. Lewy Body Dementia Current Treatment and Medical Practices

10. Lewy Body Dementia Unmet Needs

11. Lewy Body Dementia Emerging Therapies

12. Lewy Body Dementia Market Outlook

13. Country-Wise Lewy Body Dementia Market Analysis (2019–2032)

14. Lewy Body Dementia Market Access and Reimbursement of Therapies

15. Lewy Body Dementia Market Drivers

16. Lewy Body Dementia Market Barriers

17.  Lewy Body Dementia Appendix

18. Lewy Body Dementia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Lewy Body Dementia Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition

Costi Gurgu, Author of Dystopian Science Fiction Novel Green Corrosion, Honored as Book Excellence Award Finalist

Green Corrosion is recognized for its outstanding writing, design and overall market appeal out of thousands of books submitted into the Book Excellence Awards.

Costi Gurgu is the award-winning, bestselling author of original works of fiction that have appeared in Canada, the US, and Europe. He has sold 5 books and over 50 stories for which he has won 26 awards. He was three times a finalist for the Canadian Aurora Awards and one time finalist for the Book Excellence Award.

His latest sales include the anthologies Tesseracts 17, The Mammoth Book of Dieselpunk, Dark Horizons, Street Magick, Water, and Alice Unbound.

His bestselling novel RecipeArium has won three awards (Kult, Nemira, and Vladimir Colin) and was a 2018 finalist in the Aurora Awards.

His second novel, Servitude was published in October 2022. His latest novel Green Corrosion is book one of the Corrosion series, and was published in September 2023. This one-on-one interview shares Costi’s background and experience writing Green Corrosion.

Tell us about Green Corrosion.

Green Corrosion is set in a dystopian North America that has been forever ruined by society’s abject treatment of the environment. A devastating Black Rain has transformed the once-lush land into an arid wasteland, turning all water into a gel-like substance across the globe. Fresh, drinkable water has become the planet’s most precious commodity, sought after by all.

Some have chanced upon underground liquid reserves, while those with no choice but to drink gelled water become “Corrosives,” disfigured by a verdigrislike substance covering their bodies. The rich have access to a treatment that counters some, if not all, of the corrosive effects but this is out of reach to the masses.

The Golden Tower of Prince Boris shines above the otherwise derelict city of Torono. From the Golden Tower, Geo Woodman, the leader of a clan who has access to their own hidden fresh water supply, leads the fight to save the people of Torono from the dangers of corrupt leaders and the hazardous climate.

Using elements of Man vs. Man and Man vs. Nature, Green Corrosion exposes readers to a dire situation where resources are at a premium and the wrong people are in charge.

What inspired you to write Green Corrosion?

When people think of climate change, they often think of global warming, storms, drought, famine, and coastal land shrinkage.

But, the possibilities of climate change are endless.

Throughout Earth’s history, the climate has already changed, and if we do not take action, it will continue to change—drastically.

At the end of the day, we are just specks of dust in nature’s plans. Through the book, I wanted to ring the alarm on what could happen in the future and showcase how these impending changes could change us too.

How did you feel when you found out you received a Book Excellence Award?

After writing for more than 30 years, it felt wonderful to be recognized for my work. I’m honored to have received this prestigious award.

How did your background and experience influence your writing?

I’ve wanted to be a writer for as long as I can remember.

I began writing in primary school, where I was strongly influenced by Star Wars, Jules Verne and H.G. Wells.

I got serious in high school when my German Language teacher, Nadia Dorian, wife of acclaimed SF author Dorel Dorian, read some of my short stories and encouraged me to enter my first writing group, Solaris. A few years later, some authors from Solaris formed a new writers group called ProspectArt to reflect the changing nature of the SF market in Romania. I became one of the founders of this group.

My first successful writing attempt was in university when I sold my first story, Wonderful Asaara. It was published in the Science Fiction Journal, received two awards, and has been resold five times since.

After that, I became a prolific writer.

To date, my work has been published internationally, received numerous awards and been met with market success and critical acclaim, in Europe and North America. Through experience, I have come to understand the differences between European and American genre writing, and my goal is to combine the two different cultures to produce glorious hybrid stories that will appeal to both readership groups equally.

What is one message you would like readers to remember?

Green Corrosion paints a picture of what a dystopian future could look like if we lost a major resource: water. It offers readers a harrowing glimpse at a world marked by environmental degradation, corruption, and the consequences of unchecked corporate power. It also challenges conventional notions of progress, underscoring the delicate balance between technological innovation and ecological sustainability.

In our society, corporate greed and egotistical blindness have made us believe that money can save us from whatever situation we end up in, but to nature, money has no value.

We haven’t yet reached the point of no return on climate change so there is still time to salvage the world as it is. The book was designed to be a reality check to open readers eyes to what could happen if we do not stop exploiting the environment.

Purchasing the Book

Green Corrosion is available for sale on Amazon, Barnes & Noble, Apple iBooks, Kobo, Nook, Google Play and other online bookstores. Readers are encouraged to purchase their copy today: https://a.co/d/bqfHpKk

To connect with Costi and receive updates about upcoming events and new book releases, visit: https://costigurgu.com/. You can also find Costi on Facebook, Twitter and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Costi Gurgu, Author of Dystopian Science Fiction Novel Green Corrosion, Honored as Book Excellence Award Finalist